InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

Friday, January 9, 2009 General News J E 4
LOS ALTOS, Calif., Jan. 8 InteKrin Therapeutics, Inc.,will present at the 27th Annual JP Morgan Global Healthcare Conference at9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the WestinSt. Francis in San Francisco, California. InteKrin Therapeutics' President andCEO Denny Lanfear will present at the conference.

About InteKrin (

InteKrin Therapeutics is a privately-held clinical stage biopharmaceuticalcompany focused on the development and commercialization of novel drugs forthe treatment of diabetes, obesity and metabolic disease. The company's leadprogram is INT131, a late-stage non-TZD SPPARM (Selective PeroxisomeProliferator-Activated Receptor Modulator). INT131 is the result of anextensive molecular design effort to address the problematic safety concernsof TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R)(rosiglitazone), which while efficacious are associated with weight gain,edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 wasspecifically selected for its ability to separate powerful PPAR anti-diabeticefficacy from these serious TZD side effects.

INT131 is a next-generation insulin sensitizer that addresses insulinresistance, a key etiological feature in the onset and subsequent progressionof type 2 diabetes. Treating and improving insulin sensitivity in diabeticpatients by activating PPAR-gamma is an important therapeutic tool forphysicians, providing powerful glucose control and durability of effect. As aSPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned tosafely reduce insulin resistance, addressing an important unmet medical need.

InteKrin expects to complete enrollment of its 360 patient, 24-week,placebo-controlled Phase 2b study of INT131 at four doses compared to 45mgActos in Q1 09 and to have final results later this year.

To learn more about InteKrin, visit

SOURCE InteKrin Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Zix Corporation CEO Provides Corporate Update for ...
MERIAL Takes Avian Business to New Dimension